Soligenix, Inc. · NASDAQ:SNGX

Soligenix — Investor Presentation (September 2021)

24 slides from Soligenix's investor presentation, Sep 25, 2021

  1. Slide 1: Rising to the Challenges of Rare Disease Treatment

    Rising to the Challenges of Rare Disease Treatment NASDAQ: SNGX

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products

  3. Slide 3: Company Description

    3 Company Description Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need Two areas of focus:  A Specialized BioTherapeutics segment dedicated to the development of products for orph

  4. Slide 4: Investment Highlights

    4 Investment Highlights  Robust pipeline consisting of multiple fast track and/or orphan designated products, with potential for significant commercial returns of ~$2B in global annual sales  Late clinical-stage assets, one with successful Phase 3 data readout o Cutaneous T-cell lymphoma (HyBryte™

  5. Slide 5: Development Pipeline – Rare Diseases

    Development Pipeline – Rare Diseases Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market Specialized HyBryte™ (SGX301 or synthetic hypericin) Positive Phase 3 results; BioTherapeutics Cutaneous T-Cell Lymphoma (CTCL) ORPHAN & FAST TRACK DESIGNATION NDA pending* SGX942 (dusquetide) FAST TRA

  6. Slide 6: Multiple Potential Value Drivers

    6 Multiple Potential Value Drivers 2021** 2022** 2023** EU regulatory – 1H: (US) NDA 2H: (EU) MAA 1H: (US) NDA 2H: US commercial HyBryte™ * (e.g., PIP/ILAP) submission CTCL submission CTCL approval CTCL launch CTCL Expansion into 1H: Clinical protocol 2H: Initiate Ph 2a 2H: Ph 2a SGX302 * Psoriasis

  7. Slide 7: Total Addressable Global Market

    7 Total Addressable Global Market $1,200 Assumptions(1) > $1,000 $1,000 Cutaneous T-Cell Lymphoma 27,000 Patients US 20,000 Patients EU $800 Mild-to-Moderate Psoriasis 3,000,000 Patients US $ Millions 5,000,000 Patients EU $600 Pediatric Crohn’s Disease 80,000 Patients US $400 80,000 Patients EU RiV

  8. Slide 8: Specialized BioTherapeutics

    8 Specialized BioTherapeutics Targeted Approach to Treating Oncology & Inflammation

  9. Slide 9: Specialized BioTherapeutics Segment

    9 Specialized BioTherapeutics Segment Commercial Targets – Unmet Medical Needs in Oncology and Inflammation Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market Specialized BioTherapeutics HyBryte™ (SGX301 or synthetic hypericin) ORPHAN & FAST TRACK DESIGNATION Positive Phase 3 results; Cut

  10. Slide 10: Cutaneous T-Cell Lymphoma – Disease Overview

    10 Cutaneous T-Cell Lymphoma – Disease Overview  Cutaneous T-cell lymphoma (CTCL) o Rare class of Non-Hodgkin's Lymphoma (NHL) o Malignant T-cells migrate to the skin o Cancer forms patches, lesions or tumors  CTCL affects over 40,000 NHL patients worldwide; currently no cure o $250 million total

  11. Slide 11: HyBryte (SGX301) – Synthetic Hypericin Ointment + Light Activation, First-in-Class

    HyBryte™ (SGX301) – Synthetic Hypericin 11 Ointment + Light Activation, First-in-Class  Treatment safe and well-tolerated o Minimal reported adverse events ‒ Other CTCL treatments characterized by acute and chronic side effects o Uses visible fluorescent light ‒ Not carcinogenic unlike other UV pho

  12. Slide 12: HyBryte – Pivotal Phase 3 Clinical Trial

    12 HyBryte™ – Pivotal Phase 3 Clinical Trial  Highly powered, double-blind, placebo-controlled, randomized o Randomized 2:1 (HyBryte™ [synthetic hypericin 0.25%] : placebo) HyBryte™ Placebo o Cycle 1 complete: Primary Endpoint (response rate) Cycle 1: statistically significant (p=0.04) 118 subjects

  13. Slide 13: Phototherapy a mainstay treatment of early stage CTCL

    Phototherapy a mainstay treatment of 13 early stage CTCL HyBryte™ Treatment Regimen  Treating dermatologists are experienced administering phototherapy  Approximately 80% of community dermatology practices have light units available  100% of the ~50 US CTCL clinics currently administer UV phototh

  14. Slide 14: Dermatologist KOLs play pivotal role in treatment of early stage CTCL

    Dermatologist KOLs play pivotal role in 14 treatment of early stage CTCL  Most CTCL patients who go to a Key Opinion Leader (KOL) for diagnosis will remain with that KOL for their care and treatment  For those that return to their referring physician (typically for logistical reasons or travel dis

  15. Slide 15: Significant opportunity for improvement to current treatment paradigm in early stage CTCL

    15 Significant opportunity for improvement to current treatment paradigm in early stage CTCL Early Stage CTCL Treatment Paradigm Current Treatment Landscape  Because of chronic nature of early stage CTCL and long-term treatment cycles, clinicians choose Empiric Tx therapies with better safety Topic

  16. Slide 16: Advantages to commercializing CTCL in the US

    16 Advantages to commercializing CTCL in the US: smaller sales force and market access support  A concentrated prescriber base  Payers are likely to cover the drug allows for an efficient sales force and light treatment if shown to be footprint safe and efficacious o Planned launch focused on high

  17. Slide 17: HyBryte a Significant Near Term Commercial Opportunity

    17 HyBryte™ a Significant Near Term Commercial Opportunity Addressing a Clear Unmet Need  Clinicians see need for additional treatment options with fewer side effects  Most patients cycle through several treatments over course of their disease Unmet Need  Chronic nature of early stage CTCL and di

  18. Slide 18: Public Health Solutions

    18 Public Health Solutions Addressing Critical Concerns for Industry and Government

  19. Slide 19: Public Health Solutions Segment

    19 Public Health Solutions Segment Funded by Government – Medical Countermeasures (MCMs) for Civilian and Military Use Public Health Product Candidates (FDA Animal Rule) Proof-of-Concept IND Phase 1 Phase 2/3 Market Solutions** RiVax® + ThermoVax® – Vaccine NIH Contract Awards of $30M to date; ORPHA

  20. Slide 20: RiVax – Ricin Toxin Vaccine Candidate

    20 RiVax® – Ricin Toxin Vaccine Candidate  Ricin toxin vaccine of rising Heat-stable ricin vaccine provided interest to US and other countries 100% protection in a non-human primate due to recent terrorist threats and aerosol challenge model ease of castor bean procurement and ricin production Demo

  21. Slide 21: CiVax – COVID-19 Vaccine Candidate

    21 CiVax™ – COVID-19 Vaccine Candidate Spike protein and CoVaccine HT™  Pandemic response will require adjuvant demonstrated (here and here): many different vaccines to produce adequate global coverage  Balanced antibody response (including Th1) Market  Rapid distribution enabled by  Strong neut

  22. Slide 22: Experienced Management and Board of Directors

    22 Experienced Management and Board of Directors • 30 years of experience • 25 years of experience Gregg Lapointe, Christopher J. • Discovery Laboratories (COO) • Cerium Pharmaceuticals (CEO) CPA, MBA Schaber, PhD • Acute Therapeutics (Co-Founder) • Formerly of Sigma-Tau Pharmaceuticals, Chairman, •

  23. Slide 23: In Summary

    23 In Summary  Robust pipeline consisting of multiple fast track and/or orphan designated products, with potential for significant commercial returns of ~$2B in global annual sales  Late clinical-stage assets, one with successful Phase 3 data readout o Cutaneous T-cell lymphoma (HyBryte™ or SGX301

  24. Slide 24: Thank you

    24 Thank you www.soligenix.com NASDAQ: SNGX

Soligenix — Investor Presentation (September 2021) on 6ix